<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">The mechanisms underlying these coagulation abnormalities, particularly hypercoagulation, in the setting of COVID-19 are unclear. One hypothesis is that the severe inflammatory response and endothelial damage induced by COVID-19 in combination with underlying comorbidities might predispose patients to a hypercoagulable state
 <sup>
  <xref ref-type="bibr" rid="CR6">6</xref>
 </sup>. Of note, certain antiviral medications and investigational therapies given to these patients might promote thrombosis or bleeding events through drugâ€“drug interactions with antiplatelet agents and anticoagulants
 <sup>
  <xref ref-type="bibr" rid="CR41">41</xref>
 </sup>.
</p>
